HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Lessons Learned from CAR19 and Next Steps at UPENN for CAR T Cell Research in Multiple Myeloma, with Dr. Adam Cohen, MD
Lessons Learned from CAR19 and Next Steps at UPENN for CAR T Cell Research in Multiple Myeloma, with Dr. Adam Cohen, MD image
HealthTree Podcast for Multiple Myeloma
event Oct 08, 2015 / 11:00AM - 12:00PM MDT

Event Description

Dr. Carl June at the University of Pennsylvania has been working on the use of CAR T cells against blood cancers for over a decade. Work by him and his group is now bearing fruit. In a recently completed study, Dr. Adam Cohen and the team at UPENN targeted a protein not normally found on myeloma cells - CD19. The CD19 approach had been used with great results in CLL, non-Hodgkins Lymphoma and in ALL, with 80-90% response rates in ALL. Even though this target is not on the surface of most myeloma cells, they decided to try the therapy in myeloma in combination with autologous transplant. The rationale is that CAR T cells are very sensitive to even low levels of markers and that precursor myeloma cells could actually have CD19 on them. Another reason is that CD19 could actually act as an immunosuppressor, so by getting them out of the way, the treatment could do its job without the immune system kicking in to protect it. In their initial myeloma trial, the results for one high-risk patient (del17p. 1q gain and refractory to 9 prior therapies) were spectacular. She is still in complete remission over a year later. Normally, the longer the CAR T cells stick around in a patient (even 2-3 years later), the better the response. In the myeloma patients, they have not lasted as long, so Dr. Cohen describes how they are working on getting them to persist for a longer period of time. Dr. Cohen describes how they are now looking at varying the time frame in which they give the cells. They are now giving them 12-14 days after transplant. In other CAR T cell work, it could potentially be used without transplant, but because the CD19 is not normally present on myeloma cells, transplant had to be used to kill the myeloma tumor burden.  Their next target is CAR T cell treatment for BCMA because is it a safe target. Now, many other CAR T cell targets are being explored including CS1, BCMA, Kappa light chain and others. The prospects for this therapy are very exciting and Dr. Cohen and his team will continue their exciting work to make it even better over time. Clinical Trials Discussed in This Show BCMA CAR T Cells Without Transplant The Myeloma Crowd Radio Show With Dr. Adam Cohen


Schedule & Agenda

Dr. Adam Cohen and Jenny Ahlstrom

Speakers & Moderators

The panelist Adam Cohen, MD
Adam Cohen, MD

Adam D. Cohen, MD, is Director of the Myeloma Immunotherapy program and Associate Professor, Hematology/Oncology Division at the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. He is recognized as one of the world’s leading experts in CAR T cell research and treatment in myeloma. Dr. Cohen is board certified in internal medicine, medical oncology, and hematology. He is a member of the American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, American Society for Blood and Marrow Transplantation, and the American Society of Hematology. He is also a member of the Multiple Myeloma Committee, Eastern Cooperative Oncology Group and the Multiple Myeloma Panel, National Comprehensive Cancer Network. In addition, Dr. Cohen is an ad hoc reviewer for Annals of Oncology, Cytotherapy, Journal of Translational Medicine, Blood, Amyloid, and Clinical Cancer Research. He has written dozens of original articles, book chapters, and reviews on DNA vaccines, tumor immunity, multiple myeloma, amyloidosis, and stem cell transplant. Dr. Cohen received his medical degree from the University of Pennsylvania, Philadelphia, where he also completed an internal medicine residency. He completed a hematology/oncology fellowship and was a research associate in the Laboratory of Tumor Immunology at Memorial Sloan-Kettering Cancer Center, New York.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube